Журнал кардиореспираторных исследований 2025. №2/4
Тема статьи
THE IMPACT OF SACUBITRIL-VALSARTAN THERAPY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (10-15)
Авторы
I.R. Agababyan, N.G. Nizamova
Учреждение
Samarkand State Medical University
Аннотация
Background: Over the past two decades, the number of heart failure cases has doubled worldwide, and heart failure with preserved ejection fraction (HFpEF) is becoming increasingly common, posing a significant challenge to public health. Currently, there are no effective treatments for this condition, making it crucial to conduct research. Materials and Methods: This study was conducted at the Сardiological centre of Samarkand region. It was an observational study that included 48 patients diagnosed with chronic HFpEF. Key clinical and laboratory parameters were recorded before and after treatment, and statistical analysis was performed using SPSS version 28.0. Differences were considered significant if p < 0.05. Results: The patients were divided into two groups: Group 1 (n=24) received sacubutril/valsartan therapy, and Group 2 (n=24) received valsartanmonotherapy. After 16 weeks of treatment, a significant improvement in clinical and laboratory parameters was noted in patients receiving sacubutril/valsartan. The average decrease in systolic blood pressure (BP) was -10.3 ± 1.0 mmHg in the sacubutril/valsartan group compared to - 6.4 ± 0.9 mmHg in the valsartan-only group (p<0.05). Functional class improvement of CHF (Congestive Heart Failure) according to the NYHA (New York Heart Association) classification was observed in 63% of patients in Group 1 versus 42% in Group 2 (p<0.05). Conclusions: These results confirm that sacubutril/valsartan combination therapy is more effective than valsartan monotherapy in patients with congestive heart failure. Treatment with sacubutril/valsartan has shown significant reductions in blood pressure, and hospitalization rates, as well as improvements in the functional status of patients. These findings suggest that this therapy could be a promising approach for treating patients with chronic heart failure, especially those with resistant hypertension.
Ключевые слова
Heart failure with preserved ejection fraction (HFpEF), sacubitril, valsartan, New York Heart Association (NYHA), systolic blood pressure (SBP)
Литературы
1. Agababyan I. R, Nizamova N. G. Clinical and prognostic features of patients with unstable angina and chronic heart failure with preserved left ventricular ejection fraction results of conservative treatment. Web of Medicine: Journal of Medicine, Practice and Nursing. 2025; 3 (1): 386-88. DOI: 616.124-008.46:615.22 2. Agababyan I. R, Nizamova N. G. Исследование Эффективности Сакубитрил/Валсартана у Пatsiентов с Сердечной Недостаточностью: Результаты Кардиологического Центра Самаркандского Региона. New Day in Medicine (2023-2024 гг.) 2025; 3 (77): 675-83 ISSN 2181-712X. 3. Agababyan I. R, Nizamova N. G. Nizamov X.SH. Xasandjanova F.O. Анализ Факторов Риска Развития Неблагоприятных Событий у Пatsiентов с Декомпенсatsiей Хронической Сердечной Недостаточности. Вестник Ассоциatsiи Пульмонологов Центральной Азии 2025; 2 (7) 93-96. ISSN 2181-4988 4. Cheng RK, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. American Heart Journal. 2014;168(5):721–30. DOI: 10.1016/j.ahj.2014.07.008. 5. Damman K, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Failure. 2018;6(6):489–98. DOI: 10.1016/j.jchf.2018.02.004. 6. Fu S, et al. Effects of Sacubitril-Valsartan in HFpEF Patients Undergoing Peritoneal Dialysis. Frontiers in Medicine. 2021;8:657067. DOI: 10.3389/fmed.2021.657067. 7. Ho JE, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation. 2019;140(5):353–65. DOI: 10.1161/CIRCULATIONAHA.118.039136. 8. Jackson AM, et al. Sacubitril–valsartan for resistant hypertension in HFpEF. European Heart Journal. 2021;42(36):3741–3752. DOI: 10.1093/eurheartj/ehab499. 9. McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371:993– 1004. DOI: 10.1056/NEJMoa1409077. 10. Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128. 11. Solomon SD, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. The Lancet. 2012;380:1387–95. DOI: 10.1016/S0140-6736(12)61227-6. 12. Solomon SD, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 2017;5:471–482. 13. Tadic M, et al. The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more? Heart Failure Reviews. 2018;23:631–639. DOI: 10.1007/s10741-018-9701-4. 14. Upadhya B, et al. Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. Heart Failure Reviews. 2018;23:609–29. DOI: 10.1007/s10741-018-9714-z. 15. Williams B , et al. British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol,and doxazos into determine the optimal treatment for drug resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.Lancet2015; 386:2059–2068. 16. Cornuault L., et al. Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs? Front Physiol. 2022 Jul 8;13:906272. doi: 10.3389/fphys.2022.906272. PMID: 35874523; PMCID: PMC9304560. 17 . Schiattarella GG, et al. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res. 2021 Jan 21;117(2):423- 434. doi: 10.1093/cvr/cvaa217. PMID: 32666082; PMCID: PMC8599724.